Have any Questions? +01 123 444 555
DE

Lurbinectedin

According to the NCI website, lurbinectedin is a synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. . Check for active clinical trials using this agent. (NCI Thesaurus)

According to WIKI in “Small-cell carcinoma

Lurbinectedin demonstrated an overall response rate (ORR) of 35.2% in relapsed small cell lung cancer trial. Overall survival rate for patients with sensitive disease (chemotherapy-free interval of 90 days or longer) was 15.2 months, and 5.1 months for patients with resistant disease (chemotherapy-free interval of less than 90 days). [47] Lurbinectedin is currently available in the U.S. under Expanded Access Program (EAP).[48]

Summary of the following 2 studies:

Trigo J, et al "Lurbinectedin as a second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial" Lancet Oncol 2020; 21: 645-54.

Arrieta O, et al "New opportunities in a challenging disease: Lurbinectedin for relapsed small-cell lung cancer" Lancet Oncol 2020; 21: 605-607.

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute

 

Alle Wirkstoffe

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2022. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close